newsfilter
← Latest News
Earnings Call Transcripts·

Denali Therapeutics Inc. Jefferies Global Healthcare Conference - DENALI THERAPEUTICS INC

  • Explicit Guidance:

    • Q4 Revenue: Provided quarterly revenue guidance for 2026 only, with Q4 2026 expected to generate $30–32 million.
    • 2027 Outlook: No specific financial guidance provided for 2027 or beyond at this time; management stated 2027 guidance approach is not yet determined.
  • Business-Segment Outlook:

    • Avlea (Hunter Syndrome):
      • Market Share Goal: Target to become market leader by treating all new and prevalent patients, aiming to exceed the current standard of care (Aptose/Elaprase) global revenues of ~$700 million, leveraging superior brain penetrance and weight-based pricing.
      • Patient Population: U.S. addressable population is ~375 pediatric patients (75% of ~500 total); global population includes ~1,500 patients (1/3 Europe, 1/3 outside Europe).
      • Revenue Mix: Weight-based dosing in adults (25% of population) expected to drive >30% of total value.
      • Commercial Trajectory: Launch trajectory described as "better than internally expected" with overwhelming community feedback driving momentum for switching prevalent patients from current ERT.
    • Zalfilim (Sanfilippo):
      • Filing Target: BLA filing for Sanfilippo anticipated next year (FY2026/2027 cycle).
      • Readout Timing: Full dataset readout expected at World Neurology 2027 (February 2027).
      • Phase III: Confirmatory study enrollment has begun; designed as open-label with no standard of care comparator. No specific timing guidance for top-line data due to enrollment uncertainties and shifting regulatory landscape (Ultragenyx gene therapy approval).
      • Peak Potential: Market opportunity estimated to be similar to Hunter Syndrome (MPS II), though difficult to gauge due to lack of current treatment.
    • Progranulin (FTD):
      • Study Duration: Treatment duration extended from 6 to 12 months to capture proximal and distal biomarkers (neurofilament).
      • Readout Timing: Data readout expected in the first half of 2027.
      • Market Size: Addresses 6–10% of the Frontotemporal Dementia (FTD) population.
      • Approval Path: Seeking accelerated approval based on neurofilament (NFL) reduction, with precedent from Tofersen (ALS) approval; FDA alignment discussions ongoing.
    • Alzheimer's Portfolio:
      • Tau Program (DNL201): First-in-human data expected in 2027 in actual Alzheimer's patients. Targeting robust CSF tau reduction (20–50% reduction bar set) via IV delivery to ensure even brain distribution, avoiding the uneven uptake seen with intrathecal delivery.
      • Amyloid Program (DNL921):
        • Safety Data: Healthy volunteer data (2027) to assess hematology (reticulocytes) and "off-switch" mechanism (silencing when bound to TFR).
        • Efficacy Data: Early biomarker data for plaque reduction expected in Alzheimer's patients in 2027.
        • Differentiation: Unique integrated TFR binding vs. linkers (superior stability/uptake vs. competitors) and potential for sub-Q dosing.
  • Market and Competitive Outlook:

    • Pricing Strategy: U.S. Avlea price set at ~$800,000 annually for a 30kg patient, a ~60% premium over Elaprase ($500k).
    • Pricing & Reimbursement: International expansion hinges on securing pricing and reimbursement quickly following regulatory approval.
    • Competitive Landscape: Acknowledges shifts in the Sanfilippo landscape due to Ultragenyx's gene therapy approval, which raised the bar for efficacy demonstration (historical comparator vs. active control).
    • Dosing Preferences: Strategic focus on developing sub-Q dosing for Alzheimer's and potentially other programs to enable prevention settings and ease of administration, moving away from IV/Intrathecal where possible.
    • Technology Validation: Platform validation confirmed by Avlea's success; expectation that transport vehicle technology will be applied broadly across the pipeline to transform life outcomes.
  • Macro / Industry Outlook:

    • Regulatory Pathways:
      • U.S.: Compas study (Hunter) expected to open adult labeling (25% of population) and support FDA approval.
      • International: One-third of ex-U.S. markets do not require the Phase 3 COMPAS study and can leverage U.S. CPP data for accelerated pathways.
      • FDA Interaction: Active engagement with CDER and CBER regarding shifting efficacy bars in ultra-rare diseases (post-gene therapy approvals) and accelerated approval criteria for biomarkers.
    • R&D Focus: Increased emphasis on natural history data for study powering and potential use of historical controls in clinical trials due to difficulty in enrollment for ultra-rare diseases.
  • Strategic Initiatives:

    • Label Expansion: Pursuing expansion of Avlea label into adult populations to capture 30%+ of revenue value.
    • Regulatory Studies:
      • COMPAS (Hunter): Confirmatory head-to-head study vs. Elaprase; two-year endpoint completion expected end of 2027, with readout targeted for 2028.
      • Progranulin: Extended trial duration to 12 months to ensure detection of NFL decline.
    • Platform Expansion: Leveraging the validated "transport vehicle" platform to launch programs in Pompeii, FTD, and multiple Alzheimer's indications (Tau/A-beta).
    • Clinical Design Optimization:
      • Sanfilippo Phase III designed as open-label due to lack of standard of care.
      • Alzheimer's Tau program targeting even brain distribution via IV to maximize CSF knockdown compared to intrathecal approaches.
  • Risks and Headwinds to Outlook:

    • Regulatory Uncertainty: Success of accelerated approvals depends on FDA alignment regarding biomarker thresholds (e.g., NFL reduction levels) and the acceptability of historical comparators in the Sanfilippo program.
    • Enrollment Challenges: Sanfilippo Phase III enrollment timing is uncertain due to a shifting competitive landscape (gene therapy approvals).
    • Biomarker Correlation: Uncertainty remains on the specific level of biomarker reduction (e.g., NFL, Tau) required to translate into clinical benefit, though 80% CSF reduction was seen in Sanfilippo.
    • Anti-Drug Antibodies (ADA): In Sanfilippo, patients with persistent ADA failed to normalize biomarkers, potentially impacting efficacy in a subset.
    • Pricing/Reimbursement: International market access contingent on successful and rapid pricing/reimbursement negotiations post-approval.
  • Management Tone on the Future:

    • Confidence Level: High confidence in exceeding current standard of care revenues; described the launch as "very exciting" and "overwhelming."
    • Strategic Shift: Tone indicates a pivot from single-product focus to platform scaling, emphasizing the "transport vehicle" as the core story.
    • Timeline Certainty: Specific confidence in 2026 revenue guidance; more cautious/uncertain tone regarding exact timing for 2027 and beyond due to dependency on enrollment and regulatory alignment.
  • Miscellaneous:

    • Study Specifics: Sanfilippo Phase 1/2 data showed 80% average reduction in CSF heparin sulfate and normalization in a subset; 20 patients total in dataset.
    • Biomarker Specifics: Progranulin program targets glucosylsphingosine (proximal) and NFL (distal); Alzheimer's program targets CSF tau and plaque reduction.
    • Product Differentiation: Avlea's brain penetrance and weight-based dosing are key differentiators vs. Elaprase; DNL921's "on-off switch" mechanism aims to eliminate hematology issues seen with competitor molecules.
Company
DENALI THERAPEUTICS INC
Keywords
DENALI THERAPEUTICS INC